VolitionRX Ltd (NYSEMKT:VNRX) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 10th. Analysts expect VolitionRX to post earnings of ($0.14) per share for the quarter.

VolitionRX (NYSEMKT:VNRX) last released its quarterly earnings results on Thursday, May 11th. The medical research company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. On average, analysts expect VolitionRX to post $-0.56 EPS for the current fiscal year and $-0.57 EPS for the next fiscal year.

VolitionRX Ltd (NYSEMKT VNRX) opened at 3.05 on Tuesday. VolitionRX Ltd has a 12-month low of $2.92 and a 12-month high of $5.86. The firm’s market cap is $80.40 million. The stock has a 50 day moving average of $3.30 and a 200 day moving average of $3.84.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of VolitionRX in a research report on Friday, July 21st.

TRADEMARK VIOLATION WARNING: This story was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/08/volitionrx-ltd-vnrx-scheduled-to-post-earnings-on-thursday.html.

VolitionRX Company Profile

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.

Earnings History for VolitionRX (NYSEMKT:VNRX)

Receive News & Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related companies with MarketBeat.com's FREE daily email newsletter.